June 14, 2022
How an Expert Would Manage His Own Advanced Prostate CancerWith: Marc B. Garnick, MD
When facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Marc B. Garnick, MD, how he would handle his own advanced prostate cancer. Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center in Boston, MA. He is also… Read more »
August 15, 2020
New Focus on ADT in Prostate Cancer Guideline BookmarkGeorge Lundberg, MD
Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
Hormone therapy has been a mainstay in the treatment of metastatic prostate cancer. But, until now, guidelines have been short on detail. This news story outlines 38 approved additions to guidelines.
Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
June 18, 2015
ASCO 2015: Notable Reports on Prostate Cancer TreatmentEmma Shtivelman, PhD
This year’s American Society of Clinical Oncology (ASCO) annual meeting was short on any truly exciting developments in prostate cancer treatment. In stark contrast to other cancers, such as lung, breast, kidney, and melanoma, there were no reports of note on targeted and immunotherapies in prostate cancer. The two presentations summarized here offered new strategies in chemotherapy.
February 17, 2015
Now BATting: A New Treatment Approach That Uses Testosterone First, Then ADTEmma Shtivelman, PhD
Androgen deprivation therapy (ADT) has long been a mainstay in the management of prostate cancer. Indeed, the vast majority of prostate cancers depend on androgens (hormones like testosterone) for their growth. Lowering testosterone levels with ADT is a reasonable approach. But it comes with two sets of problems.